A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07643766 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: ENV-294
OTHER: Placebo

Sponsor

Enveda Therapeutics